We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Pharmseal is a software company that aims to disrupt clinical trial management. The company claims that companies typically use multiple applications for managing clinical trials from one or more vendors. This increases cost and complexity. Pharmaseal asserts that its cloud Business-2-Business (B2B) platform, Engility, simplifies control by providing a single management portal. The platform allows information to be centralised and accessed from a single platform. Pharmaseal claims that Engility will allow companies to save cost and time and enable them to bring life-saving drugs to market faster. The company will utilise 31% of the investment for commercialisation and marketing, 49% for product development, 13% for IT infrastructure, and 7% for administrative/legal/miscellaneous activities.

Pitch Rated

78%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £532,311
Jeeni is an online entertainment service that aims to harness the growing reach of streamed music. It has close to 350 million subscribers and a growth rate of 39% Year-on-Year (YoY) providing billion-dollar revenues for digital disruptors. The Jeeni prototype was launched in April 2019. The company asserts that it offers artists an ethical revenue share. Five revenue streams are operating in parallel on the Jeeeni platform, namely, subscription-based memberships, online masterclasses, bespoke hardware sales, pay-to-view streamed events, and branded merchandise sales. The company's long term goal is to surpass its target paid subscriber numbers, achieve high subscriber growth and exit by acquisition. The investment raised will be used to further scale the company's capacity globally and build its mass artist showcases.

Pitch Rated

77%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £118,854
Creative Hub is a fast-growing cloud software platform for creative people to store, share files, and collaborate on projects. The collaboration tools also allow users to chat in real-time, and add comments on images, allowing creative teams to work faster and deliver better results. Creative Hub enables users to order professional art & photographic prints, or physical 3D prints, which are produced at its print production facilities in London(UK) and Dusseldorf (Germany). The platform currently has 40,000 active users which are growing day by day. With the investment, the company will drive growth through marketing and launch its New York production facility.

Pitch Rated

76%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £286,992
Rightangled is a DNA testing company backed by NHS that delivers services to consumers and medical/fitness specialists. The company is a full CQC healthcare provider license that has achieved registration with Bupa, a leading medical insurance company. The company is now planning to move into AI with a solid database. Rightangled has received excellent customer reviews with 5* on Google and 4.5* on Trustpilot. With the proceeds, the company will seek to launch its application, create a strong AI central system, and grow into new markets (US& UAE).

Pitch Rated

75%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £311,690
DMD has made its digital content distribution enterprise in the last two years. Along with that, it has developed a global cinema TVOD (Transactional Video On Demand product). The company has built a long-term distribution partnership with OTT companies, telephone/IPTV and major cable that lead the wealthiest portion of the Pay TV market, providing service to 17 million two-way homes in 19 nations in Latin America. DMD's revenue has increased by 93% YoY 2017-2018, which will help the company in reaching EBITDA breakeven in Q3 of 2019. DMD has established relationships with distributors and leading sales agents in Europe and the USA. With the proceeds, the company will acquire bigger commercial films, increase its global footprint by launching the company in Asia, Africa, and Europe, and supplement its current output with classic titles.

Pitch Rated

70%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £145,000
Coras is a new technology ticketing platform connecting the world's tickets to people who wish to buy them for any event or activity. The portal has connected multiple ticketing systems into a single system opening up this market to new players for the first time. Coras's marketplace suppliers include West End Theatre tickets, Premier League football and tourist attractions. On the distribution side, it has partnered with Europe's largest airline, Ryanair, Frontier Airlines in the US and Tix.co in Australia. It has also signed other distribution partners in Europe & Asia which it'll announce soon. Ticketing is a $150 billion industry and Coras wants to be a  strong contender in this segment. The company will use 85% of investment in software development and build the best product possible that can scale with its distribution and supplier partners.

Pitch Rated

66%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £625,760
TC BioPharm is an immunotherapy company. It has used its patented technology to harness the power of a particular part of the immune system, Gamma Delta T-cells (GDT), to negate cancer cells in the human body. TC BioPharm has treated terminally ill patients with acute myeloid leukaemia in approved clinical trials garnering positive responses from multiple patients. The company has received regulatory approval from the Medicines and Healthcare products Regulatory Agency (MHRA) to run a COVID-19 clinical trial to address the global pandemic. TC BioPharm aims to use its current technology to provide a frozen product that can be manufactured cost-effectively and distributed globally. The company has already raised over £7 million in the last 15 months. It will use the investment to take its clinical trials forward in COVID-19 and cancer.

Pitch Rated

59%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £1,753,067
Trackd is a unique, award-winning music platform where artists create and audiences discover. With more than 261,000 users in 161 countries, this simple and intuitive application enables artists to record, collaborate, inspire, and share their ideas around the world. It has featured artists including Dave Stewart (Eurythmics), Valeras, and Blossoms. The app also features a ground-breaking social sharing tools “VirtualVinyl™” and allows video creation directly in the app. Trackd is exploring new and existing partnerships such as Rotor Video and Audio Technica as well as Apple for the next release. The company has already established a stellar team, built a 5-star app and have gained a huge amount of users in the past 3 years. The proceeds will be used for working capital, cash flow requirements, future upgrades, marketing, sponsorship, and events.

Pitch Rated

54%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £118,950
C-Major is a medical technology company. It asserts that over 2 million people suffer a Needle Stick Injury (NSI) every year and are at risk of contracting blood-borne viruses such as Hepatitis and HIV. It aspires to resolve this crisis by bringing to market its patented medical device, Controlled Helical Retraction Device, to prevent NSIs. The company argues that the device contains a ‘Helical Track’ mechanism for controlled acceleration of the needle during retraction as well as a ‘Sealed Port’ to minimise any blood splatter. C-Major endeavours to disrupt the $5.5 billion safety syringe market with its product. It is backed by the UK 'Innovation Seed' fund. C-Major will use the investment to complete the final design of its product for manufacture and assembly ahead of a Series A funding round in 2021.

Pitch Rated

53%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £211,595
Anastasis Biotec (AB) is a company that is developing a human protein-based product, Syntana-4 (S-4), that inhibits Cancer Stem Cells (CSC) - the growth engine of cancer. The global cancer drug market was at ~$200 billion in 2019. S-4 will initially target use for patients with relapsed prostate cancer which caused 3.8% of global cancer deaths in 2018. The company asserts that S-4 will have low manufacturing costs, making it affordable, enabling ‘mass-market’ sales. AB has raised £450,000 in equity convertible loans and grants in 2019 & 2020, including an Innovate-UK award. It is also aiming to progress S-4 further in collaboration with the University of Chicago’s cancer stem cell therapeutics Research and development (R&D) program. The company will use the investment to complete lab-testing before starting clinical trials.

Pitch Rated

53%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £270,543
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph